ArriVent Biopharma Collaborates with Lepu BioPharma to Develop and Commercialize MRG007 for the Treatment of Gastrointestinal Cancers

Shots:

• ArriVent & Lepu Biopharma entered into an exclusive license agreement for MRG007, where ArriVent will get rights to develop & market MRG007 (ADC) globally excl. Greater China (mainland China, Hong Kong, Macau & Taiwan)
• As per the terms, Lepu Biopharma will receive upfront, near-term milestones ($47M cash) & development, regulatory & sales milestones of ~1.16B, plus net sales-based tiered royalties outside Greater China
• In addition, preclinical studies of MRG007 has demonstrated antitumor activity in GI cancer models & a favorable therapeutic index. IND submission is expected in H1’25, with an initial clinical focus on CRC, pancreatic, & other GI cancers

Ref: Globenewswire | Image: ArriVent & Lepu Biopharma

Related News:- ArriVent BioPharma Collaborates with Alphamab to Develop Antibody Drug Conjugates for Treating Cancers

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com